Comparison of topical tofacitinib and 0.1% hypochlorous acid in a murine atopic dermatitis model
Abstract Background Topical administration of PR022, 0.05% hypochlorous acid (HOCl) in gel has been demonstrated to be beneficial in a chronic murine atopic dermatitis model. In a follow up study we tested a higher concentration (0.1%) of PR022 HOCl gel in comparison to the Janus kinase inhibitor to...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-07-01
|
Series: | BMC Pharmacology and Toxicology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40360-018-0232-3 |
id |
doaj-4b4f6f17c2564633a111e56149d1b4e7 |
---|---|
record_format |
Article |
spelling |
doaj-4b4f6f17c2564633a111e56149d1b4e72020-11-25T00:11:29ZengBMCBMC Pharmacology and Toxicology2050-65112018-07-011911810.1186/s40360-018-0232-3Comparison of topical tofacitinib and 0.1% hypochlorous acid in a murine atopic dermatitis modelTomoki Fukuyama0Sarah Ehling1Jenny Wilzopolski2Wolfgang Bäumer3Department of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State UniversityDepartment of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State UniversityDepartment of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State UniversityDepartment of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State UniversityAbstract Background Topical administration of PR022, 0.05% hypochlorous acid (HOCl) in gel has been demonstrated to be beneficial in a chronic murine atopic dermatitis model. In a follow up study we tested a higher concentration (0.1%) of PR022 HOCl gel in comparison to the Janus kinase inhibitor tofacitinib, both of which are currently in clinical phase studies for treatment of human atopic dermatitis. Methods The effect of topically administered HOCl (0.1%) in gel was compared to a topical formulation of tofacitinib (0.5%) in a therapeutic setting on atopic dermatitis-like lesions in NC/Nga mice as well as itch behaviour. NC/Nga mice were sensitized with house dust mite allergen. After reaching visible lesions, mice were treated either topically with HOCl or tofacitinib or gel vehicle for 17 days. After termination of the study, dorsal root ganglia were isolated for ex vivo stimulation and skin samples were taken for cytokine determination in inflamed skin. Results When administered onto lesional skin of NC/Nga mice, both HOCl and tofacitinib reduced lesions and scratching behaviour. The reduced inflammatory response by HOCl and tofacitinib treatment was demonstrated by diminished inflammatory cytokines in affected skin tissue from NC/Nga mice. Dorsal root ganglia neurons re-stimulated with a range of mediators of itch showed a reduced response compared to the vehicle control mice, when isolated from tofacitinib or HOCl treated mice. Conclusions These data indicate a similar beneficial potential of topical high dose PR022 HOCl (0.1%) in gel and tofacitinib, in a translational murine model of atopic dermatitis.http://link.springer.com/article/10.1186/s40360-018-0232-3Atopic dermatitisDorsal root gangliaHypochlorous acidTofacitinibIgEIL-4 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Tomoki Fukuyama Sarah Ehling Jenny Wilzopolski Wolfgang Bäumer |
spellingShingle |
Tomoki Fukuyama Sarah Ehling Jenny Wilzopolski Wolfgang Bäumer Comparison of topical tofacitinib and 0.1% hypochlorous acid in a murine atopic dermatitis model BMC Pharmacology and Toxicology Atopic dermatitis Dorsal root ganglia Hypochlorous acid Tofacitinib IgE IL-4 |
author_facet |
Tomoki Fukuyama Sarah Ehling Jenny Wilzopolski Wolfgang Bäumer |
author_sort |
Tomoki Fukuyama |
title |
Comparison of topical tofacitinib and 0.1% hypochlorous acid in a murine atopic dermatitis model |
title_short |
Comparison of topical tofacitinib and 0.1% hypochlorous acid in a murine atopic dermatitis model |
title_full |
Comparison of topical tofacitinib and 0.1% hypochlorous acid in a murine atopic dermatitis model |
title_fullStr |
Comparison of topical tofacitinib and 0.1% hypochlorous acid in a murine atopic dermatitis model |
title_full_unstemmed |
Comparison of topical tofacitinib and 0.1% hypochlorous acid in a murine atopic dermatitis model |
title_sort |
comparison of topical tofacitinib and 0.1% hypochlorous acid in a murine atopic dermatitis model |
publisher |
BMC |
series |
BMC Pharmacology and Toxicology |
issn |
2050-6511 |
publishDate |
2018-07-01 |
description |
Abstract Background Topical administration of PR022, 0.05% hypochlorous acid (HOCl) in gel has been demonstrated to be beneficial in a chronic murine atopic dermatitis model. In a follow up study we tested a higher concentration (0.1%) of PR022 HOCl gel in comparison to the Janus kinase inhibitor tofacitinib, both of which are currently in clinical phase studies for treatment of human atopic dermatitis. Methods The effect of topically administered HOCl (0.1%) in gel was compared to a topical formulation of tofacitinib (0.5%) in a therapeutic setting on atopic dermatitis-like lesions in NC/Nga mice as well as itch behaviour. NC/Nga mice were sensitized with house dust mite allergen. After reaching visible lesions, mice were treated either topically with HOCl or tofacitinib or gel vehicle for 17 days. After termination of the study, dorsal root ganglia were isolated for ex vivo stimulation and skin samples were taken for cytokine determination in inflamed skin. Results When administered onto lesional skin of NC/Nga mice, both HOCl and tofacitinib reduced lesions and scratching behaviour. The reduced inflammatory response by HOCl and tofacitinib treatment was demonstrated by diminished inflammatory cytokines in affected skin tissue from NC/Nga mice. Dorsal root ganglia neurons re-stimulated with a range of mediators of itch showed a reduced response compared to the vehicle control mice, when isolated from tofacitinib or HOCl treated mice. Conclusions These data indicate a similar beneficial potential of topical high dose PR022 HOCl (0.1%) in gel and tofacitinib, in a translational murine model of atopic dermatitis. |
topic |
Atopic dermatitis Dorsal root ganglia Hypochlorous acid Tofacitinib IgE IL-4 |
url |
http://link.springer.com/article/10.1186/s40360-018-0232-3 |
work_keys_str_mv |
AT tomokifukuyama comparisonoftopicaltofacitiniband01hypochlorousacidinamurineatopicdermatitismodel AT sarahehling comparisonoftopicaltofacitiniband01hypochlorousacidinamurineatopicdermatitismodel AT jennywilzopolski comparisonoftopicaltofacitiniband01hypochlorousacidinamurineatopicdermatitismodel AT wolfgangbaumer comparisonoftopicaltofacitiniband01hypochlorousacidinamurineatopicdermatitismodel |
_version_ |
1725403741439393792 |